Continuing its push into gene therapies, Biogen has agreed to partner with Capsigen to engineer adeno-associated virus capsids to deliver gene therapies for various CNS and neuromuscular disease targets. With the deal, Biogen gains access to Capsigen’s Transcription-Dependent Directed Evolution (TRADE™) platform that can screen and identify capsids with enhanced levels of infectivity and transduction and are highly specific to the target cells of interest. The alliance offers Biogen yet another shot on goal in improving its gene therapy delivery technologies, complementing its recent deals with ViGeneron and CEVEC Pharmaceuticals.